MedTrace Logo

Bone Marrow Derived Mononuclear Cells for Ischemic Cardiomyopathy

NCT01144221 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-04-09

No results posted yet for this study

Summary

This is an evaluative, monocentric study in patients with chronic ischemic heart disease and left bundle branch block who received an ICD-CRT. It is an early investigation on the safety and effects of a single administration of bone marrow derived mononuclear cells after implantation of an ICD-CRT device as an adjunct to CRT and usual drug treatment.

Conditions

Interventions

PROCEDURE

Intramyocardial Cell therapy

Intramyocardial Cell therapy in patients with chronic ischemic heart disease after ICD CRT Implantation

Sponsors & Collaborators

  • Kai Jaquet, PhD, DSc

    lead INDUSTRY

Principal Investigators

  • Korff Krause, Dr. med. · Asklepios proresearch

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2013-05-31
Completion
2015-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01144221 on ClinicalTrials.gov